Compare BOSC & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOSC | LNAI |
|---|---|---|
| Founded | 1990 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 23.2M |
| IPO Year | 1996 | N/A |
| Metric | BOSC | LNAI |
|---|---|---|
| Price | $4.71 | $0.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 83.2K | ★ 294.4K |
| Earning Date | 11-25-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $48,333,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.87 | ★ N/A |
| Revenue Growth | ★ 19.49 | N/A |
| 52 Week Low | $3.25 | $0.81 |
| 52 Week High | $6.72 | $14.00 |
| Indicator | BOSC | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 50.03 | N/A |
| Support Level | $4.56 | N/A |
| Resistance Level | $4.83 | N/A |
| Average True Range (ATR) | 0.24 | 0.00 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 68.49 | 0.00 |
BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.